Mechanisms of action of EGFR tyrosine kinase receptor incorporated in extracellular vesicles

Mechanisms of action of EGFR tyrosine kinase receptor incorporated in extracellular vesicles

EGFR and some of the cognate ligands extensively traffic in extracellular vesicles (EVs) from different biogenesis pathways. EGFR belongs to a family of four homologous tyrosine kinase receptors (TKRs). This family are one of the major drivers of cancer and is involved in several of the most frequen...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Zanetti-Domingues, LC, Martin-Fernandez, ML, Huber, V
Format:	Journal article
Język:	English
Wydane:	MDPI 2020

Podobne zapisy

Mechanisms of Action of EGFR Tyrosine Kinase Receptor Incorporated in Extracellular Vesicles
od: Laura C. Zanetti-Domingues, i wsp.
Wydane: (2020-11-01)

Cooperation and interplay between EGFR signalling and extracellular vesicle biogenesis in cancer
od: Zanetti-Domingues, LC, i wsp.
Wydane: (2020)

Cooperation and Interplay between EGFR Signalling and Extracellular Vesicle Biogenesis in Cancer
od: Laura C. Zanetti-Domingues, i wsp.
Wydane: (2020-12-01)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
od: Xu H, i wsp.
Wydane: (2019-07-01)

Extracellular Vesicles As Mediators of Resistance to EGFR-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Preclinical Models
od: M. Pérez-Capó, i wsp.
Wydane: (2023-11-01)

Mechanisms of resistance to EGFR tyrosine kinase inhibitors
od: Lihua Huang, i wsp.
Wydane: (2015-09-01)

Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer
od: Lu Yang, i wsp.
Wydane: (2022-06-01)

Radiation-Induced Tumor-Derived Extracellular Vesicles Combined with Tyrosine Kinase Inhibitors: An Effective and Safe Therapeutic Approach for Lung Adenocarcinoma with EGFR19Del
od: Yao Li, i wsp.
Wydane: (2024-12-01)

HIV Activates the Tyrosine Kinase Hck to Secrete ADAM Protease-Containing Extracellular Vesicles
od: J.-H. Lee, i wsp.
Wydane: (2018-02-01)

Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and IGF-1R
od: Cornelius Hempel, i wsp.
Wydane: (2017-01-01)

Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma
od: Igor Makhlin, i wsp.
Wydane: (2019-11-01)

An extracellular receptor tyrosine kinase motif orchestrating intracellular STAT activation
od: Katri Vaparanta, i wsp.
Wydane: (2022-11-01)

Structural Insight and Development of EGFR Tyrosine Kinase Inhibitors
od: Tasia Amelia, i wsp.
Wydane: (2022-01-01)

Extracellular vesicle-associated tyrosine kinase-like orphan receptors ROR1 and ROR2 promote breast cancer progression
od: Barnabas Irmer, i wsp.
Wydane: (2023-07-01)

Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers
od: Aude I. Ségaliny, i wsp.
Wydane: (2015-03-01)

Editorial: Discovery of EGFR tyrosine kinase inhibitors for cancer treatment
od: Panupong Mahalapbutr, i wsp.
Wydane: (2024-02-01)

Extracellular Vesicles Act as Nano-Transporters of Tyrosine Kinase Inhibitors to Revert Iodine Avidity in Thyroid Cancer
od: Ramya Lakshmi Rajendran, i wsp.
Wydane: (2021-02-01)

Moving the Needle Cautiously in Targeting One of the Most Often Acquired Receptor Tyrosine Fusion (RET Fusion) Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors
od: Shannon S. Zhang, MD, i wsp.
Wydane: (2022-08-01)

Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with <i>EGFR</i> Mutations
od: Kenichi Suda, i wsp.
Wydane: (2021-06-01)

Immunotherapy strategies for EGFR-mutated advanced NSCLC after EGFR tyrosine-kinase inhibitors failure
od: Xingyuan Li, i wsp.
Wydane: (2023-10-01)

Mechanisms of receptor tyrosine kinase activation in cancer
od: Zhenfang Du, i wsp.
Wydane: (2018-02-01)

Crystal structure of the Sema-PSI extracellular domain of human RON receptor tyrosine kinase.
od: Kinlin L Chao, i wsp.
Wydane: (2012-01-01)

Action Mechanisms of Small Extracellular Vesicles in Inflammaging
od: Rocío Mato-Basalo, i wsp.
Wydane: (2022-04-01)

Osimertinib – effective treatment of NSCLC with activating EGFR mutations after progression on EGFR tyrosine kinase inhibitors
od: Marcin Skrzypski, i wsp.
Wydane: (2017-09-01)

Primary Resistance to EGFR Tyrosine Kinase Inhibitors (TKIs): Contexts and Comparisons in EGFR-Mutated Lung Cancer
od: Keigo Kobayashi
Wydane: (2023-12-01)

BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations.
od: Daniel B Costa, i wsp.
Wydane: (2007-10-01)

EGFR tyrosine kinase activity and Rab GTPases coordinate EGFR trafficking to regulate macrophage activation in sepsis
od: Xuedi Zhang, i wsp.
Wydane: (2022-11-01)

Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer
od: Zhe Zhang, i wsp.
Wydane: (2019-11-01)

Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and PDGFR-β related to anticancer drug resistance
od: Tim Fischer, i wsp.
Wydane: (2018-01-01)

A preliminary results of integrated chemotherapy with EGFR receptor tyrosine kinase inhibitors in patients with non-small-cell-lung cancer harboring EGFR mutation
od: K. K. Laktionov, i wsp.
Wydane: (2019-06-01)

miR-494 in Extracellular Vesicles as a Potent Biomarker of Chronic Myeloid Leukemia Treatment with Tyrosine Kinase Inhibitors
od: Tatsuki Shibuta, i wsp.
Wydane: (2022-06-01)

Proteolytic Cleavage of Receptor Tyrosine Kinases
od: Hao Huang
Wydane: (2021-04-01)

Receptor Tyrosine Kinases — Expanding Horizons
od: Sassan Hafizi
Wydane: (2014-06-01)

Extracellular phosphorylation of a receptor tyrosine kinase controls synaptic localization of NMDA receptors and regulates pathological pain.
od: Kenji Hanamura, i wsp.
Wydane: (2017-07-01)

Mechanisms of Activation of Receptor Tyrosine Kinases: Monomers or Dimers
od: Ichiro N. Maruyama
Wydane: (2014-04-01)

In Vitro Activation and Inhibition of Recombinant EGFR Tyrosine Kinase Expressed in Escherichia coli
od: Jihene Elloumi-Mseddi, i wsp.
Wydane: (2013-01-01)

Afatinib and Necitumumab in EGFR-Mutant NSCLC with Acquired Resistance to Tyrosine Kinase Inhibitors
od: Nathaniel J. Myall, MD, i wsp.
Wydane: (2025-02-01)

ALGORITHMS FOR MANAGEMENT OF PATIENTS WITH ADVERSE EVENTS ON THERAPY WITH TYROSINE KINASE INHIBITORS EGFR
od: D. D. SAKAEVA
Wydane: (2017-06-01)

Remodeling of tumor microenvironments by EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer
od: Soomin Kim, i wsp.
Wydane: (2025-02-01)

The Prediction Of Epidermal Growth Factor Receptor Mutation And Prognosis Of EGFR Tyrosine Kinase Inhibitor By Serum Ferritin In Advanced NSCLC
od: Wu Z, i wsp.
Wydane: (2019-10-01)